Navigation Links
GEN Reports on Growing Reliance on Microfluidics Technology
Date:1/22/2009

NEW ROCHELLE, N.Y., Jan. 22 /PRNewswire/ -- Biotechnology companies are building on what they have learned about microfluidics techniques over the past decade and are expected to drive this market toward $1.9 billion in three years, reports Genetic Engineering and Biotechnology News (GEN); (www.genengnews.com). The technology offers a number of advantages, including reducing reagent consumption, increasing speed and analytical performance, multiparameter testing, and user friendliness, according to the January 15 issue of GEN.

"The globalization of life science research and an increasing trend toward novel diagnostic development, particularly point of care, are providing a significant boost toward a greater acceptance of microfluidics methodologies," says John Sterling, Editor in Chief of GEN.

Much of drug discovery focuses on finding inhibitors of enzyme targets such as kinases, phosphatases, and proteases. Caliper Life Sciences created its Mobility Shift Assay to interrogate druggable enzymes. It combines the advantages of capillary electrophoresis with microfluidics technology for the direct measurement of substrate and product.

Biosite has developed protein array technologies that contain microcapillaries for controlling the flow of fluids in immunoassay processes. The protein array format uses several different microcapillary designs to control the contact of sample with reagents and to direct the flow of fluid throughout the protein array. For example, after a blood sample is added to the array, a special internal filter separates cells from plasma. Next a capillary directs the sample into a chamber that contains dried immunoassay reagents. After an incubation time that is determined by another microcapillary element of the array, the sample next flows down a capillary path and interacts with an antibody array. The interactions are detected in the company's Triage(R) Meters that scan the array device with a laser diode.

Other companies covered in the GEN article include ChipShop, Genefluidics, Paraytec, CellASIC, and DiscoveRx.

For a copy of the January 15 issue of GEN, please call (914) 740-2122, or email: ebicovny@liebertpub.com

Genetic Engineering and Biotechnology News (www.genengnews.com), which is published 21 times a year by Mary Ann Liebert, Inc., is the most widely read biotechnology news magazine worldwide. It includes articles on Drug Discovery, Bioprocessing, OMICS, Biobusiness, and Clinical Research and Diagnostics.

Contact: John Sterling, Editor in Chief, Genetic Engineering and Biotechnology News (914) 740-2196, jsterling@genengnews.com


'/>"/>
SOURCE Genetic Engineering and Biotechnology News
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Novozymes Reports Strong 2008 Results
2. International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCools New Investigational UroCool System
3. Neogen Reports Best Quarter in Its 26-Year History
4. AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain
5. Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS
6. GEN Reports Growing Focus on PI3-Kinase Pathway in Cancer Research
7. The Female Health Company Reports Record Results for Fiscal Year 2008, at High End of Guidance
8. Encorium Reports Third Quarter 2008 Financial Results
9. Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
10. SPO Medical Reports Nine Month Period Ending September 2008
11. Sinovac Reports Third Quarter 2008 Unaudited Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample ... the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
Breaking Biology Technology:
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
Breaking Biology News(10 mins):